Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 10Urogenital Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Prostate Cancer Metastatic 1Neoplasms by Site 1Neoplasms 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-Resistant Prostate Cancer 1Genital Neoplasms, Male 1Genital Diseases, Male 1

Interventions

niraparib 1gallium 68 PSMA-11 1darolutamide 1apalutamide 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Prostatic Diseases × apalutamide × Clear all
NCT02578797 2023-11-09

A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study

Aragon Pharmaceuticals, Inc.

Phase 1 Completed
45 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡